Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Work In Process (2018 - 2024)

Historic Work In Process for Pharma (IGC) over the last 7 years, with Q3 2024 value amounting to $2000.0.

  • Pharma's Work In Process fell 8181.82% to $2000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $2000.0, marking a year-over-year decrease of 8181.82%. This contributed to the annual value of $18000.0 for FY2023, which is 9691.78% down from last year.
  • Pharma's Work In Process amounted to $2000.0 in Q3 2024, which was down 8181.82% from $36000.0 recorded in Q2 2024.
  • Pharma's Work In Process' 5-year high stood at $3.9 million during Q3 2020, with a 5-year trough of $2000.0 in Q3 2024.
  • Moreover, its 5-year median value for Work In Process was $2.2 million (2020), whereas its average is $1.7 million.
  • In the last 5 years, Pharma's Work In Process skyrocketed by 139717.74% in 2020 and then plummeted by 9691.78% in 2023.
  • Over the past 5 years, Pharma's Work In Process (Quarter) stood at $2.2 million in 2020, then increased by 0.41% to $2.2 million in 2021, then plummeted by 71.56% to $628000.0 in 2022, then plummeted by 98.25% to $11000.0 in 2023, then crashed by 81.82% to $2000.0 in 2024.
  • Its Work In Process stands at $2000.0 for Q3 2024, versus $36000.0 for Q2 2024 and $11000.0 for Q3 2023.